Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-449-1 | CAS number: 818-08-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 January 2017 to 31 January 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- January 2001
- Deviations:
- yes
- Remarks:
- The dose interval was extended allowing exposure through the pre-implantation period by dosing from gestation day 0 through to 19. To evaluate the known target organ toxicity, the thymus gland was collected and weighed for each dam.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Dibutyltin oxide
- EC Number:
- 212-449-1
- EC Name:
- Dibutyltin oxide
- Cas Number:
- 818-08-6
- Molecular formula:
- C8H18OSn
- IUPAC Name:
- dibutylstannanone
- Test material form:
- solid: particulate/powder
- Remarks:
- Light, white powder
- Details on test material:
- - Expiration Date: Stable through use on study.
- Storage: Ambient (18 to 29 °C), protected from light.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Hsd:Sprague Dawley® SD®
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: Approximately 9 to 9.5 weeks of age at time of receipt.
- Weight at study initiation: 158 to 215 g, at randomisation.
- Housing: The animals were individually housed in solid bottom cages with nonaromatic bedding.
- Diet: Ad libitum
- Water: Ad libitum tap water was available via an automatic watering system.
ENVIRONMENTAL CONDITIONS
- Temperature: 68 to 79 °F
- Humidity (%): 30 to 70 %
- Photoperiod (hrs dark / hrs light): Fluorescent lighting was provided for approximately 12 hours per day.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- peanut oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Formulations of the test material were prepared by mixing the appropriate amount of vehicle with the appropriate amount of test material at nominal concentrations of 0.15, 0.6, and 1.2 mg/mL. Formulations were prepared as needed and were stored at room temperature.
The control group received the vehicle in the same manner as the treated groups. The vehicle and test material formulations were continually stirred prior to and throughout dose administration. Individual doses were based on the most recent body weights.
VEHICLE
- Amount of vehicle: Dose volume of 5 mL/kg. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dosing formulations prepared for the study were evaluated for homogeneity and concentration. Appropriate samples were collected using a positive displacement pipette, while stirring, and placed into amber glass scintillation vials. Upon receipt of the authorisation to finalise the main study report, the retained backup samples were discarded.
Dosing formulation samples were collected as follows:
Concentration/homogeneity analysis: 0.5 mL from 0.15 and 1.2 mg/mL dose concentrations were sampled at weekly intervals. Six samples were collected from each of the top, middle and bottom, with two analysed and four back up samples.
The averaged result from homogeneity analysis served as concentration verification.
Concentration analysis: 0.5 mL from 0, 0.15, 0.6 and 1.2 mg/mL dose concentrations were sampled at weekly and 3-week intervals. Six samples were collected from the middle stratum, with two analysed and four back up samples.
The samples, including backup samples, were stored at ambient temperature pending analyses or final disposition.
Stability analysis of the dosing formulations was not conducted because the stability of the dosing formulations at the concentrations used on study has been established for 13 days at ambient temperature.
All analytical work was conducted using an analytical method developed and validated under MPI Research. Dose formulations were verified to be the concentrations stated within the acceptable range of variability, for homogeneity and concentration analytical results.
Reference Standard: Test material (Correction Factor: 1.028 for purity)
LC-MS Conditions: Liquid chromatography system equipped with a Thermo BETASIL C18 column, 50 x 2.1 mm, with a gradient flow of 88:12 water:acetic acid with 0.05 % trimethylamine (TEA) (mobile phase A), and 88:12 isopropyl alcohol (IPA):acetic acid with 0.05 % TEA (mobile phase B) at a flow rate of 0.6 mL/minute. The analyte was detected using an LC-MS/MS system operated in the positive ionisation mode at a mass to charge (m/z) ratio of 293 for the precursor ion and 251 for the product ion.
Analysis Description: Prior to analysis, samples were diluted with 88:12 IPA:acetic acid (diluent) to within the range of the calibration curve. Vehicle samples were diluted with diluent using a dilution factor of 10. An aliquot of each sample was injected into the LC-MS/MS system for analysis.
Regression Type: Linear, unweighted
Study Sample Storage Conditions: Ambient, protected from light.
Storage Stability: All samples were analysed within the established storage stability.
Run Acceptance Criteria
System Suitability Test Standards: Injection repeatability (peak area and retention time) ≤10% RSD (relative standard deviation)
Calibration Standards:
1. Accuracy within ±10 % of the nominal concentration
2. Coefficient of determination (R^2) ≥0.99
Performance Check Standards (Same preparation as the System Suitability Standard):
1. Periodically injected so that no more than 10 samples are bracketed by performance check standards. Samples are considered valid if bracketed by passing performance check standard injections.
2. Accuracy within ±10 % of the nominal concentration
Blank Injections: ≤20 % of the limit of quantitation (LOQ)
Assessments
- Homogeneity:
1. Average concentration within ±15 % of the nominal concentration
2. Precision ≤15 % RSD
- Concentration:
1. Average concentration within ±15 % of the nominal concentration
2. Precision ≤15 % RSD
3. Vehicle (control) samples < effective limit of quantitation (ELOQ)
Results:
Analytical run 1: System sustainability test (SST) injection 1: Retention time (tR): 1.816 min, peak area 7596
Analytical run 1: SST injection 2: tR: 1.823 min, peak area 7537
Analytical run 1: SST injection 3: tR: 1.816 min, peak area 7456
Mean for analytical run 1: tR: 1.816 min, peak area 7530
% Relative standard deviation (RSD): tR 0.218 min, peak area 0.933
Analytical run 2: SST injection 1: tR: 1.806 min, peak area 11684
Analytical run 2: SST injection 2: tR: 1.812 min, peak area 11658
Analytical run 2: SST injection 3: tR: 1.806 min, peak area 11601
Mean for analytical run 2: tR: 1.808 min, peak area 11648
% RSD: tR 0.219 min, peak area 0.367
Analytical run 1: Performance check 1: 9.987354 μg/mL nominal concentration, 9.850389 μg/mL calculated concentration; 98.6 % recovery
Analytical run 1: Performance check 2: 9.987354 μg/mL nominal concentration, 9.646217 μg/mL calculated concentration; 96.6 % recovery
Analytical run 1: Performance check 3: 9.987354 μg/mL nominal concentration, 9.878215 μg/mL calculated concentration; 98.9 % recovery
Analytical run 3: Performance check 1: 9.994358 μg/mL nominal concentration, 9.866436 μg/mL calculated concentration; 98.7 % recovery
Analytical run 3: Performance check 2: 9.994358 μg/mL nominal concentration, 10.063415 μg/mL calculated concentration; 100.7 % recovery
Conclusion:
A total of 32 samples were analysed (24 reported results) for the test material in dosing formulations using a validated method. The analytical data demonstrated acceptable performance of the method for all reported results.
Deviation: Analytical Method Deviation: In analytical run 2, the performance check 2 failed to meet acceptance criterion for recovery (±10 %), therefore the results of the run were not reportable as samples were not bracketed by passing performance check injections. The backup samples were analysed in run 3 (on a different instrument) and the run met all acceptance criteria. - Details on mating procedure:
- - Impregnation procedure: Purchased timed pregnant.
- Duration of treatment / exposure:
- GD 0 to 19
- Frequency of treatment:
- Once daily at approximately the same time each day (± 2 h from the GD 0 dose).
- Duration of test:
- GD 0 to 19
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.75 mg/kg bw/day
- Dose / conc.:
- 3 mg/kg bw/day
- Dose / conc.:
- 6 mg/kg bw/day
- No. of animals per sex per dose:
- 25 females per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The oral route is one of the potential routes of human exposure to this test material.
The dose levels were selected by the Sponsor on the basis of available data from a previously conducted pilot developmental toxicity study. The pilot study showed that at the dose level of 9.5 mg/kg/day, 40 % of the dams were unable to tolerate the dosing schedule and had to be euthanised. In addition, dams exposed to 9.5 mg/kg/day weighed significantly less than controls in the early stages of gestation. The severity of these endpoints on the dam was the basis for selecting the high dose of 6 mg/kg/day, with the middle and low doses of 3.0 and 0.75 mg/kg/day being selected as following a geometric progression factor of 4 and 2, respectively.
- Rationale for animal assignment: Using a standard, by weight, randomidation procedure, 100 female animals (weighing 158 to 215 g, at randomisation) were assigned to the control and treatment groups. All animals were given a detailed clinical examination and body weights were recorded prior to selection and before dosing on GD 0. The Study Director reviewed GD 0 body weight and detailed observation data for all animals and gave final approval for assignment to study.
Animals assigned to study had body weights within ± 20 % of the mean body weight. Extra animals obtained, but not placed on study, were euthanised by carbon dioxide inhalation followed by an MPI Research SOP approved method to ensure death. The carcasses were discarded.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily
- Cage side observations: All animals were observed for morbidity, mortality, injury, and the availability of food and water.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily from GD 0 through 20 (75 minutes, ±15 minutes, post-dose on dosing days), each animal was removed from the cage and given a detailed clinical examination. On occasion, clinical observations were recorded at unscheduled intervals. The observations included, but were not limited to, evaluation of the skin, fur, eyes, ears, nose, oral cavity, thorax, abdomen, external genitalia, limbs and feet, as well as evaluation of respiration.
Veterinary Observations: On occasion, veterinary observations were conducted during the course of the study. All treatments and observations were recorded. The medical treatments and observations are not reported but are maintained in the study file.
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights for all animals were measured and recorded on GD 0, 3, 6, 9, 12, 15, 18, and 20. Individual body weight change was calculated for the following GD intervals: GD 0-3, 3-6, 6-9, 9-12, 12-15, 15-18, 18-20 and 0-20. Adjusted body weight (GD 20 body weight minus gravid uterine weight) and adjusted body weight change (GD 0 to 20) were also calculated.
FOOD CONSUMPTION: Yes
- Time schedule for examinations: Food consumption was measured and recorded on the corresponding body weight days and calculated for the same intervals.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day #: On GD 20, each surviving female was euthanised by carbon dioxide inhalation followed by an SOP approved method to ensure death and immediately subjected to a cesarean section.
- Organs examined: Maternal necropsies were conducted without knowledge of the treatment groups in order to minimise bias. The skin was reflected from a ventral midline incision to examine mammary tissue and locate any subcutaneous masses. The abdominal cavity was then opened, and the uterus was exposed. The uterus was excised, and the gravid uterine weight was recorded. Beginning at the distal end of the left uterine horn, the location of viable and nonviable foetuses, early and late resorptions for each uterine horn, and the total number of implantations were recorded. The number of corpora lutea on each ovary was also recorded.
The foetuses were removed by making a dorsal incision longitudinally along both uterine horns. The embryonic membrane of each foetus was gently removed, and each foetus was pulled away from the placenta, fully extending the umbilical cord. The placentae were examined grossly.
Uteri from females that appeared nongravid were opened and placed in 10 % ammonium sulfide solution for detection of implantation sites. If no foci were detected, the female was considered to be nonpregnant.
A complete necropsy was performed on all euthanised in extremis and surviving dams under procedures approved by a veterinary pathologist. Special emphasis was placed on structural abnormalities or pathologic changes that may have influenced the pregnancy. The presence of lesions or other abnormal conditions in the dam were noted and described in the study records. Additionally, the thymus gland from each animal was collected, weighed, and preserved in 10 % neutral buffered formalin for possible further evaluation. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
Each implant was categorised according to the following criteria. Viable foetuses responded to touch. Nonviable foetuses did not respond to touch and had no signs of autolysis. Late resorptions were characterised by recognisable foetal form, but undergoing autolysis. Early resorptions were characterised as implantation sites that had no recognisable foetal characteristics. - Fetal examinations:
- Foetal examinations were conducted without knowledge of the treatment groups in order to minimise bias. Each foetus was individually weighed, sexed, tagged, and examined for external malformations and variations. Foetuses were then euthanised by intraperitoneal injection of euthanasia solution.
Approximately one-half of the foetuses in each litter were placed in Bouin’s solution and the remaining foetuses were fixed in alcohol.
- External examinations: Yes: All per litter.
- Soft tissue examinations: Yes: Approximately half per litter. All foetuses fixed in Bouin’s solution were examined for soft tissue defects using the Wilson razor-blade sectioning technique.
- Skeletal examinations: Yes: Approximately half per litter. The foetuses fixed in alcohol were macerated in potassium hydroxide, stained with Alizarin Red S, and cleared with glycerin by a method similar to that described by Dawson for subsequent skeletal examination.
- Head examinations: No
Foetal findings were classified as malformations or developmental variations under procedures approved by a developmental toxicologist. On occasion, additional information to clarify or identify a visceral or skeletal observation was documented. These comments are not reported, but are maintained in the study data. Mechanical artifacts (i.e., tail removed and discarded) occurred during examination and processing of the foetuses. These artifacts are not reported, but are maintained in the study data. - Statistics:
- The raw data were tabulated within each time interval, and the mean and standard deviation were calculated for each endpoint by sex and group.
Parental In-life Data
Group pair-wise comparisons: Gestation body weights, gestation body weight changes, gestation food consumption, adjusted body weights, adjusted body weight changes (GD 0 - 20) and thymus weight (absolute and relative to adjusted GD 20 bodyweight).
Uterine and Ovarian Examinations
Fischer’s exact test: Pregnancy index, malformations by finding and exam type (external, visceral and skeletal)-litter incidence and variations by finding and exam type (external, visceral and skeletal)-litter incidence. Foetal and litter incidences are reported, but only the litter incidences were statistically analysed.
Group pair-wise comparison: Gravid uterine weights, corpora lutea/dam, total implantations/dam, litter size/dam, viable foetuses/dam, total number resorptions/dam, number early resorptions/dam and number late resorptions/dam.
Arcsin-square-root transformation: Foetal sex ratio (% males/litter), % pre-implantation loss and % post-implantation loss.
Descriptive statistics: Non-viable foetuses/dam.
Covariate analysis: Mean foetal body weights. - Indices:
- Pregnancy Index = (No. females pregnant / No. females with evidence of mating) x 100
Post-implantation Loss = ((No. implantations - No. viable foetuses) / No. implantations) x 100
Pre-implantation Loss = ((No. corpora lutea - No. implantations) / No. corpora lutea) x 100 - Historical control data:
- No. of studies: 2
No. females: 135
No. pregnant: 124
No. not pregnant: 1
No. died pregnant: 0
No. females with all resorptions: 0
No. pregnant by stain: 0
No. females with viable foetuses: 124
No. of litters evaluated: 124
No. external foetuses evaluated: 1 588
No. visceral foetuses evaluated: 794
No. skeletal foetuses evaluated: 794
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- No adverse effect of the test material at 0.75 and 3.0 mg/kg/day was observed from the detailed clinical examinations. Red material around the nose was observed at least once in 3/25 and 5/25 animals in the 0.75 and 3.0 mg/kg/day dose groups, respectively and was also observed in 6/25 animals in the 6.0 mg/kg/day group. A similar finding was not observed among the control animals. Due to its sporadic occurrence among the treated animals generally observed only on 1 or 2 days during the study and in many instances only during the first week, its presence while likely test material related, was not considered adverse. Other clinical findings observed in the 0.75 and 3.0 mg/kg/day animals occurred at low incidence or with similar frequency to controls and were considered unrelated to the test material. In the 6.0 mg/kg/day group, clinical findings observed with increased frequency and considered test material related and adverse included low body carriage, red material around the nose, thin appearance, loss of skin elasticity, and pale body colour.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- All animals in the control, 0.75, and 3.0 mg/kg/day groups survived to scheduled termination on GD 20. In the 6.0 mg/kg/day group, animals 4512 and 4525 were euthanised in extremis on GD 12 and GD 9, respectively. Both animals had clinical signs of toxicity that included decreased activity, low body carriage, red material around the nose/mouth, hunched posture, pale body color, and thin unkempt appearance. Likewise both animals lost weight from the start of treatment and had low food consumption. The moribundity observed in these animals was considered test material-related. All other animals in the 6.0 mg/kg/day group survived to scheduled termination.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- No effect of the test material at dose levels of 0.75 and 3.0 mg/kg/day was observed on gestation body weights and body weight change. At 6.0 mg/kg/day, mean body weights were statistically lower than mean control values on GD 18 (-8 %) and 20 (-9 %). Mean body weight change in this group was lower than mean control values over much of gestation and statistically lower over GD 0 to 3 (-24 %), GD 6 to 9 (-34 %) and over the entire GD 0 to 20 treatment period (-19 %). Considerable variability in gestation body weight change was observed in the 6.0 mg/kg/day dose group. This was attributed to low weight gain and/or weight loss in several animals (4510, 4511, 4516, and 4524) that failed to retain pregnancies with foetuses and at GD 20 had uterine implantations comprised entirely of resorbing foetuses (100 % post-implantation loss). These effects on gestation body weights and body weight change at 6.0 mg/kg/day were considered test material related correlating with adverse pregnancy outcomes in several animals.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean gravid uterine weights, adjusted GD 20 body weights and adjusted weight change GD 0 to 20 in the test material-treated groups were comparable to mean control values.
Lower thymus weights, absolute and relative to the adjusted GD 20 body weight, were observed in the test material-treated groups. Mean absolute thymus weights were 19 %, 34 %, and 44 % lower than the mean control value in the 0.75, 3.0, and 6.0 mg/kg/day dose groups, respectively and relative to the adjusted GD 20 body weights, were 20 %, 35 %, and 37 % lower, respectively. These differences in thymus weights, absolute and relative to adjusted GD 20 body weight in the test material-treated groups relative to controls were statistically significant and considered test material related. In the context of this study, the toxicological significance of this decrease in thymus weight in the absence of histopathological examination is unclear. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- No effect of the test material at 0.75 and 3.0 mg/kg/day was observed from the maternal macroscopic examinations. The few findings observed among these animals occurred at low incidence or with similar frequency as controls and were considered unrelated to the test material. At 6.0 mg/kg/day, small thymus was observed with increased frequency. This was observed in the two animals euthanised in extremis in this group and 4/23 animals that survived to scheduled termination. Other maternal macroscopic findings observed in the 6.0 mg/kg/day group occurred at low incidence or similar to controls and were considered unrelated to the test article.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- - Food consumption: No effect of the test material at dose levels of 0.75 and 3.0 mg/kg/day was observed on gestation food consumption. At 6.0 mg/kg/day, mean food consumption was statistically lower than mean control values over GD 6 to 9 (-14 %), GD 9 to 12 (-13 %), and GD 15 to 18 (-17 %). The considerable variability in food consumption observed in this group was largely attributable to low food consumption in those females with failed pregnancies as discussed previously. Mean food consumption in the 6.0 mg/kg/day group over the entire treatment period (GD 0 to 20) was 15.47g/animal/day and 9 % lower (not statistically significant) than the 17.09 g/animal/day observed in controls.
Maternal developmental toxicity
- Number of abortions:
- not specified
- Pre- and post-implantation loss:
- effects observed, treatment-related
- Description (incidence and severity):
- No effect of the test material at 0.75 and 3.0 mg/kg/day was observed on GD 20 uterine implantation parameters.
Statistically significant decreases in mean post-implantation loss in the 0.75 mg/kg/day dose group relative to controls were considered incidental, not adverse, and unrelated to the test material.
In the 6.0 mg/kg/day group, no statistically significant changes in corpora lutea count or uterine implantation data were observed relative to controls.
In the 6.0 mg/kg/day group, notable increases in mean post-implantation loss (25.70 %) were observed. Changes in this parameter in the 6.0 mg/kg/day dose group were also outside the range of recent historical control data for the laboratory maximum study values were 5.35 % for post-implantation loss. Changes were largely attributable to the four females in the group with all resorption sites in utero (100 % post-implantation loss). - Total litter losses by resorption:
- effects observed, treatment-related
- Description (incidence and severity):
- Four females in the 6.0 mg/kg/day group (4510, 4511, 4516, and 4524) had uterine implantations comprised entirely of resorbing foetuses (100 % post-implantation loss).
The increased incidence of females with all resorption sites in utero was considered test material related and adverse.
In the 6.0 mg/kg/day group, notable increases in mean number of resorption sites (total and early)/dam (2.7) relative to controls (5.40 % and 0.7, respectively) were observed. Changes in these parameters in the 6.0 mg/kg/day dose group were also outside the range of recent historical control data for the laboratory maximum study values were 0.7 resorption sites (total and early)/dam. Changes were largely attributable to the four females in the group with all resorption sites in utero (100 % post-implantation loss). - Early or late resorptions:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Statistically significant increases in mean number of resorption sites (total and early) in the 0.75 mg/kg/day dose group relative to controls were considered incidental, not adverse, and unrelated to the test material.
- Dead fetuses:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant increases in mean number of viable foetuses and litter size in the 0.75 mg/kg/day dose group relative to controls were considered incidental, not adverse, and unrelated to the test material.
In the 6.0 mg/kg/day group a decrease in number of viable foetuses/dam (9.7 vs. 12.5 in controls) were observed. Changes in these parameters in the 6.0 mg/kg/day dose group were also outside the range of recent historical control data for the laboratory maximum study values were 13.5 viable foetuses/dam). Changes were largely attributable to the four females in the group with all resorption sites in utero (100 % post-implantation loss). - Changes in pregnancy duration:
- not specified
- Changes in number of pregnant:
- effects observed, treatment-related
- Description (incidence and severity):
- Pregnancy index in the control, 0.75, 3.0, and 6.0 mg/kg/day groups was 96 %, 96 %, 92 %, and 88 %, respectively. There were one, one, two, and three nonpregnant females in the control, 0.75, 3.0, and 6.0 mg/kg/day groups, respectively. Two of the nonpregnant females in the 6.0 mg/kg/day group were euthanised in extremis.
Overall, there were 24, 24, 23, and 18 litters with GD 20 foetuses for evaluation in the control, 0.75, 3.0, and 6.0 mg/kg/day dose groups, respectively.
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- 3 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- mortality
- pre and post implantation loss
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- No effect of the test material was observed on foetal body weights. Mean foetal body weights distinguished by sex and for the combined sexes, in the test material-treated groups were comparable to mean control values.
- Reduction in number of live offspring:
- not examined
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- No effect of the test material was observed on foetal sex ratios (percent male foetuses/animal). Mean sex ratios ranged from 45.2 % to 48.8 % in the treated groups and were comparable to the mean of 47.1 % in controls.
- Changes in litter size and weights:
- not specified
- Changes in postnatal survival:
- not examined
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No effect of the test material was observed from the foetal external examinations. No malformations were observed among foetuses in the 0.75 and 6.0 mg/kg/day groups. In the 3.0 mg/kg/day group, the only external malformation observed was misshapen tongue. The litter incidence for this finding was 17.4 % (4/23 litters affected) and comparable to the 12.5 % (3/24 litters affected) in controls. Filamentous tail and absence of an anus were observed in one control foetus. No external developmental variations were observed among the control and test material-treated foetuses.
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No effect of the test material was observed from the foetal skeletal examinations. No skeletal malformations were observed among foetuses from the control and the test material-treated groups. Litter incidences for ossification variations observed in the test material-treated groups were comparable to control and no effect of treatment was observed from these data.
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No effect of the test material was observed from the foetal visceral examinations. No malformations were observed among foetuses in the control, 0.75, and 6.0 mg/kg/day dose groups. In the 3.0 mg/kg/day group the only visceral malformation observed was folded retina. This was observed in a single foetus and in the absence of a similar malformation among foetuses in the 6.0 mg/kg/day group, its occurrence on study was considered spontaneous and unrelated to the test material. The litter incidence of an irregular palatal rugae pattern, a visceral variation, in the control, 0.75, and 3.0 mg/kg/day treated groups was 4.2 %, 12.5 %, and 26.1 %, respectively. The higher incidence of this variation in these treated groups did not differ statistically from controls and in the absence of a similar finding among foetuses in the 6.0 mg/kg/day group, was not considered test material related. The occurrence of a smaller than normal thyroid, a visceral variation in one foetus at 6.0 mg/kg/day was considered incidental and unrelated to test article.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 3 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 6 mg/kg bw/day (actual dose received)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects occurring together with maternal toxicity effects, but not as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- no
- Relevant for humans:
- not specified
Any other information on results incl. tables
Summary of Maternal and Developmental Observations at Uterine Examination
Endpoint |
0 mg/kg/day |
0.75 mg/kg/day |
3.0 mg/kg/day |
6.0 mg/kg/day |
No. females on study |
25 |
25 |
25 |
25 |
No. not pregnant |
1 |
1 |
2 |
3 |
No. pregnant |
24 |
24 |
23 |
22 |
Pregnancy index percent |
96.0 |
96.0 |
92.0 |
88.0 |
No. females with resorptions |
0 |
0 |
0 |
4 |
No. females with viable foetuses GD 20 |
24 |
24 |
23 |
18 |
Summary of Maternal and Developmental Observations at Uterine Examination
Endpoint |
0 mg/kg/day |
0.75 mg/kg/day |
3.0 mg/kg/day |
6.0 mg/kg/day |
|
Corpora lutea No. per animal |
Mean |
15.4 |
16.1 |
16.0 |
15.4 |
SD |
2.30 |
2.02 |
3.01 |
2.43 |
|
N |
24 |
24 |
23 |
18 |
|
Implantation sites No. per animal |
Mean |
13.2 |
14.3 |
14.2 |
12.5 |
SD |
1.89 |
2.35 |
1.67 |
2.42 |
|
N |
24 |
24 |
23 |
22 |
|
Pre-implantation loss % per animal |
Mean |
12.91 |
11.03 |
9.80 |
14.66 |
SD |
14.050 |
9.759 |
10.112 |
15.271 |
|
N |
24 |
24 |
23 |
18 |
|
Viable foetuses |
Mean |
12.5 |
14.1* |
13.5 |
9.7 |
SD |
1.96 |
2.36 |
1.78 |
5.42 |
|
N |
24 |
24 |
23 |
22 |
|
Foetal sex ration % males per animal |
Mean |
47.1 |
45.2 |
46.6 |
48.8 |
SD |
16.45 |
15.21 |
11.34 |
11.35 |
|
N |
24 |
24 |
23 |
18 |
|
Post-implantation loss % per anima |
Mean |
5.40 |
1.46* |
4.89 |
25.70 |
SD |
5.626 |
2.952 |
5.687 |
39.370 |
|
N |
24 |
24 |
23 |
22 |
|
Nonviable Foetuses No. per animal |
Mean |
0 |
0 |
0 |
0 |
SD |
0 |
0 |
0 |
0 |
|
N |
24 |
24 |
23 |
22 |
|
Litter size No. per animal |
Mean |
12.5 |
14.1* |
13.5 |
9.7 |
SD |
1.96 |
2.36 |
1.78 |
5.42 |
|
N |
24 |
24 |
23 |
22 |
|
Resorptions: early + late No. per animal |
Mean |
0.7 |
0.2* |
0.7 |
2.7 |
SD |
0.75 |
041 |
0.82 |
4.26 |
|
N |
24 |
24 |
23 |
22 |
|
Resorptions: early No. per animal |
Mean |
0.7 |
0.2* |
0.7 |
2.7 |
SD |
0.75 |
0.41 |
0.83 |
4.22 |
|
N |
24 |
24 |
23 |
22 |
|
Resorptions: late No. per animal |
Mean |
0 |
0 |
0 |
0 |
SD |
0 |
0 |
0.21 |
0.21 |
|
N |
24 |
24 |
23 |
22 |
* Significantly different from control (p<0.05).
Summary of Gestation Body Weight Values (g)
Study Interval (Day) |
0 mg/kg/day |
0.75 mg/kg/day |
3.0 mg/kg/day |
6.0 mg/kg/day |
||||||||
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
|
0 |
187.7 |
13.87 |
24 |
188.1 |
14.5 |
24 |
187.3 |
14.93 |
23 |
186.3 |
13.16 |
22 |
3 |
205.0 |
15.09 |
24 |
205.2 |
13.75 |
24 |
206.1 |
16.25 |
23 |
199.5 |
15.07 |
22 |
6 |
215.4 |
14.72 |
24 |
216.3 |
14.23 |
24 |
218.3 |
17.18 |
23 |
210.0 |
16.60 |
22 |
9 |
232.4 |
15.6 |
24 |
232.5 |
14.84 |
24 |
234.7 |
18.18 |
23 |
221.1 |
22.80 |
22 |
12 |
248.2 |
16.57 |
24 |
247.2 |
17.2 |
24 |
250.4 |
20.35 |
23 |
233.6 |
29.55 |
22 |
15 |
265.5 |
16.66 |
24 |
265.7 |
17.17 |
24 |
270.0 |
21.28 |
23 |
248.5 |
38.22 |
22 |
18 |
303.9 |
17.65 |
24 |
310.0 |
20.51 |
24 |
311.5 |
26.81 |
23 |
280.3* |
51.34 |
22 |
20 |
334.4 |
19.82 |
24 |
344.6 |
24.61 |
24 |
344.9 |
30.34 |
23 |
305.4* |
62.95 |
22 |
* Significantly different from control (p<0.05).
Summary of Gestation Body Weight Change Values (g)
Study Interval (Day) |
0 mg/kg/day |
0.75 mg/kg/day |
3.0 mg/kg/day |
6.0 mg/kg/day |
||||||||
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
|
0 - 3 |
17.3 |
4.80 |
24 |
17.1 |
4.10 |
24 |
18.8 |
3.55 |
23 |
13.2* |
5.95 |
22 |
3 – 6 |
10.5 |
4.57 |
24 |
11.1 |
3.60 |
24 |
12.2 |
2.96 |
23 |
10.5 |
4.68 |
22 |
6 – 9 |
17.0 |
3.85 |
24 |
16.3 |
3.12 |
24 |
16.4 |
4.18 |
23 |
11.2* |
8.96 |
22 |
9 – 12 |
15.8 |
3.20 |
24 |
14.7 |
4.19 |
24 |
15.7 |
3.70 |
23 |
12.5 |
8.40 |
22 |
12 – 15 |
17.4 |
5.43 |
24 |
18.5 |
4.65 |
24 |
19.5 |
6.71 |
23 |
15.0 |
11.03 |
22 |
15 – 18 |
38.4 |
6.25 |
24 |
44.4 |
6.66 |
24 |
41.6 |
7.71 |
23 |
31.7 |
15.13 |
22 |
18 – 20 |
30.5 |
4.75 |
24 |
34.5 |
6.61 |
24 |
33.3 |
4.71 |
23 |
25.1 |
13.74 |
22 |
0 - 20 |
146.7 |
11.73 |
24 |
156.5 |
17.38 |
24 |
157.5 |
21.08 |
23 |
119.1† |
56.38 |
22 |
*Significantly different from control (p<0.05).
† Significantly different from control (p<0.01).
Summary of Gestation Food Consumption Values (g/animal/day)
Study Interval (Day) |
0 mg/kg/day |
0.75 mg/kg/day |
3.0 mg/kg/day |
6.0 mg/kg/day |
||||||||
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
Mean |
SD |
N |
|
0 - 3 |
12.28 |
2.037 |
24 |
12.89 |
1.562 |
24 |
13.16 |
1.875 |
23 |
12.21 |
4.377 |
22 |
3 – 6 |
14.97 |
2.567 |
24 |
15.22 |
1.817 |
24 |
16.54 |
2.886 |
23 |
15.20 |
3.306 |
22 |
6 – 9 |
16.74 |
2.852 |
24 |
16.81 |
1.702 |
24 |
16.19 |
1.729 |
23 |
14.44* |
4.538 |
22 |
9 – 12 |
16.93 |
1.624 |
24 |
16.69 |
1.322 |
24 |
17.22 |
1.719 |
23 |
14.77* |
5.286 |
22 |
12 – 15 |
17.61 |
1.531 |
24 |
17.53 |
1.985 |
24 |
18.38 |
1.876 |
23 |
15.89 |
6.273 |
22 |
15 – 18 |
22.25 |
2.497 |
24 |
21.97 |
2.113 |
24 |
22.14 |
3.270 |
23 |
18.55† |
7.008 |
22 |
18 – 20 |
19.69 |
2.453 |
24 |
20.83 |
2.268 |
24 |
21.15 |
2.822 |
23 |
18.11 |
7.265 |
22 |
0 - 20 |
17.09 |
1.530 |
24 |
17.25 |
1.182 |
24 |
17.66 |
1.798 |
23 |
15.47 |
4.692 |
22 |
* Significantly different from control (p<0.05).
† Significantly different from control (p<0.01).
Summary of GD 20 Maternal Thymus Weights
Group (mg/kg/day) |
Thymus Weight (g) |
Thymus/ Adjusted GD20 Body Weight (%) |
0 |
0.239 |
0.0891 |
0.75 |
0.193* |
0.0716* |
3.0 |
0.158* |
0.0581* |
6.0 |
0.134* |
0.0558* |
* Significantly different from control (p < 0.01).
Historical Control Data
Parameter |
Mean |
Minimum |
Maximum |
Pregnancy Index (%) |
99.50 |
99.0 |
100.0 |
Corpora Lutea (Mean No. per Animal) |
15.35 |
15.1 |
15.6 |
Implantation Sites (Mean No. per Animal) |
13.7 |
13.3 |
14.1 |
Preimplantation Loss (Mean % per Animal) |
9.950 |
8.82 |
11.08 |
Viable Foetuses (Mean No. per Animal) |
13.05 |
12.6 |
13.5 |
Foetal Sex Ratio (Mean % Males per Animal) |
49.20 |
47.4 |
51.0 |
Post-implantation Loss (Mean % per Animal) |
4.755 |
4.16 |
5.35 |
Nonviable Foetuses (Mean No. per Animal) |
0 |
0 |
0 |
Litter Size (Mean No. per Animal) |
13.05 |
12.6 |
13.5 |
Resorptions: Early and Late (Mean No. per Animal) |
0.65 |
0.6 |
0.7 |
Resorptions: Early (Mean No. per Animal) |
0.65 |
0.6 |
0.7 |
Resorptions: Late (Mean No. per Animal) |
0 |
0 |
0 |
Mean Foetal Body Weight Male (g) |
4.05 |
4.02 |
4.08 |
Mean Foetal Body Weight Female (g) |
3.850 |
3.83 |
3.87 |
Mean Foetal Body Weight Males and Females (g) |
3.950 |
3.93 |
3.97 |
Historical Control Data - Litter Evaluations
Parameter |
Total No. |
Max % / Study |
||
Foetuses |
Litters |
Foetuses |
Litters |
|
External malformation |
||||
Body, umbilicus, ophalocele |
2 |
2 |
0.2 |
2.0 |
Skeletal malformation |
||||
Cervical vertebra€, neural arch(es), misshapen |
1 |
1 |
0.6 |
4.0 |
Visceral malformations |
||||
Head, retina, folded retina |
1 |
1 |
0.2 |
1.0 |
Skeletal variation |
||||
Rib(s), rudimentary |
158 |
65 |
29.8 |
68.0 |
Rib(s), unilateral full rib |
5 |
4 |
1.8 |
8.0 |
Skull, hyoid, not ossified |
1 |
1 |
0.2 |
1.0 |
Skull, palatine, irregular ossification |
62 |
20 |
11.3 |
24.0 |
Sternum, sternebra(e), misaligned |
10 |
10 |
1.6 |
10.1 |
Sternum, sternebra(e), not ossified |
11 |
11 |
1.8 |
11.1 |
Analytical Calibration Results
Analytical Run |
Standard Identification |
Nominal Concentration (μg/mL) |
Calculated Concentration (μg/mL) |
% Recovery |
Coefficient of Determination (R^2) |
1 |
Standard 1 |
2.003113 |
2.053228 |
102.5 |
0.9984 |
Standard 2 |
3.004669 |
2.925588 |
94.7 |
||
Standard 3 |
6.00939 |
6.206982 |
103.3 |
||
Standard 4 |
10.015564 |
9.868528 |
98.5 |
||
Standard 5 |
12.519455 |
12.220998 |
97.6 |
||
Standard 6 |
15.023346 |
15.300160 |
101.8 |
||
3 |
Standard 1 |
2000934 |
2.039972 |
102.0 |
0.9992 |
Standard 2 |
3.001401 |
3.036667 |
101.2 |
||
Standard 3 |
6.002802 |
6.047250 |
100.7 |
||
Standard 4 |
10.004669 |
9.7400897 |
97.9 |
||
Standard 5 |
12.505837 |
12.400897 |
99.2 |
||
Standard 6 |
15.007004 |
15.206865 |
101.3 |
Analysis of the Test Material in Dosing Formulations – Week 1
Dose Level (mg/kg/day) |
Sample Identification |
Nominal Concentration (mg/mL) |
Calculated Concentration (mg/mL) |
Average Calculated Concentration (mg/mL) |
% Recovery |
Average % Recovery |
% Relative Standard Deviation |
0 |
Replicate 1 |
0.00 |
BLQ |
BLQ |
NA |
NA |
NA |
Replicate 2 |
BLQ |
||||||
0.75 |
Top replicate 1 |
0.15 |
0.1501 |
0.1416 |
100.1 |
94.4 |
5.976 |
Top replicate 2 |
0.1514 |
101.0 |
|||||
Middle replicate 1 |
0.1296 |
86.4 |
|||||
Middle replicate 2 |
0.1386 |
92.4 |
|||||
Bottom replicate 1 |
0.1360 |
90.7 |
|||||
Bottom replicate 2 |
0.1437 |
95.8 |
|||||
3.0 |
Replicate 1 |
0.60 |
0.6070 |
0.5916 |
101.2 |
98.6 |
3.691 |
Replicate 2 |
0.5761 |
96.0 |
|||||
6.0 |
Top replicate 1 |
1.20 |
1.1520 |
1.1083 |
96.0 |
92.4 |
3.485 |
Top replicate 2 |
1.1598 |
96.6 |
|||||
Middle replicate 1 |
1.0905 |
90.9 |
|||||
Middle replicate 2 |
1.0709 |
89.2 |
|||||
Bottom replicate 1 |
1.1020 |
91.8 |
|||||
Bottom replicate 2 |
1.0745 |
89.5 |
BLQ: Below the Limit of Quantitation (< 20.0000 μg/mL).
NA: Not Applicable/Not Available
Analysis of the Test Material in Dosing Formulations – Week 3
Dose Level (mg/kg/day) |
Sample Identification |
Nominal Concentration (mg/mL) |
Calculated Concentration (mg/mL) |
Average Calculated Concentration (mg/mL) |
% Recovery |
Average % Recovery |
% Relative Standard Deviation |
0 |
Backup replicate 1* |
0.00 |
BLQ |
BLQ |
NA |
NA |
NA |
Backup replicate 2* |
BLQ |
NA |
|||||
0.75 |
Backup replicate 1* |
0.15 |
0.1362 |
0.1445 |
90.8 |
96.4 |
9.135 |
Backup replicate 2* |
0.1529 |
101.9 |
|||||
3.00 |
Backup replicate 1* |
0.60 |
0.5932 |
0.6007 |
98.9 |
100.1 |
1.764 |
Backup replicate 2* |
0.6082 |
101.4 |
|||||
6.00 |
Backup replicate 1* |
1.20 |
1.2518 |
1.2083 |
104.3 |
100.7 |
5.088 |
Backup replicate 2* |
1.1649 |
97.1 |
BLQ: Below the Limit of Quantitation (< 20.0000 μg/mL).
NA: Not Applicable/Not Available
* Backup samples were analysed due to the initial run failing to meet acceptance criteria for performance check 2.
Analysis of Dosing Formulations
- Homogeneity: Analyses of the low- and high-dose formulations (0.15 and 1.20 mg/mL) used for dosing the first week of study confirmed they were homogeneous as prepared meeting the laboratory’s acceptance criteria of 100 ± 15 % of nominal for the average percent recovery and percent Relative Standard Deviation (RSD) ≤ 10.
Dose Level (mg/kg/day) |
Nominal Concentration (mg/mL) |
Average Calculated Concentration (mg/mL) |
Average % Recovery* |
% Relative Standard Deviation |
0.75 |
0.15 |
0.1416 |
94.4 |
5.976 |
6.0 |
1.20 |
1.1083 |
92.4 |
3.485 |
* Average % recovery was calculated from the nominal concentration.
- Concentration: Mean concentrations of formulations used for dosing in Weeks 1 and 3 ranged between 92.4 % and 100.7 % of nominal with percent RSDs ranging between 1.764 and 8.135, confirming that animals were receiving the appropriate dose levels when the formulations were administered at 5 mL/kg. No test material was detected in the control samples.
Dose Level (mg/kg/day) |
Nominal Concentration (mg/mL) |
Average Calculated Concentration* (mg/mL) |
Average % Recovery*† |
% Relative Standard Deviation* |
0 |
0.00 |
BLQ |
NA |
NA |
0.75 |
0.15 |
0.1416 – 0.1445 |
94.4 – 96.4 |
5.976 – 8.135 |
3.0 |
0.60 |
0.5916 – 0.6007 |
98.6 – 100.1 |
1.764 – 3.691 |
6.0 |
1.20 |
1.1083 – 1.2083 |
92.4 – 100.7 |
3.485 – 5.088 |
* Results are the range of values determined during Weeks 1 and 3.
† Average % recovery was calculated from the nominal concentration.
BLQ: Below the Limit of Quantitation (< 20.0000 μg/mL).
NA: Not applicable.
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of the study the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity with the test material was 3.0 mg/kg/day. At dose levels of 0.75, 3.0, and 6.0 mg/kg/day, the test material was not teratogenic in the rat.
- Executive summary:
This study was conducted for to evaluate the possible adverse effects of the test article following repeated oral exposure to pregnant animals according to OECD Test Guideline 414 and in compliance with GLP.
This evaluation included systemic toxicity, female reproductive performance, and evaluation of the fetuses. The vehicle, peanut oil, or test material was administered to time-mated female Hsd:Sprague Dawley® SD® rats once daily via oral gavage from Gestation Day (GD) 0 through 19.
Observations of the animals included clinical signs, body weights, food consumption, and anatomical pathology including a uterine examination. All foetuses were given an external and visceral or skeletal examination.
Analytical results for formulations used for dosing in Weeks 1 and 3 confirmed homogeneity and concentration levels ranged between 92.4 % and 100.7 % of nominal. No test material was detected in the control samples.
All animals in the control, 0.75, and 3.0 mg/kg/day groups survived to scheduled termination on GD 20. At 6.0 mg/kg/day, two animals were euthanized in extremis with clinical signs of toxicity, low body weights, low body weight change, and low food consumption. A low incidence of red material around the mouth was observed in the test material-treated groups but not considered adverse due to its sporadic occurrence generally early in the study. No other maternal effects at dose levels ≤3.0 mg/kg/day were observed from clinical findings, gestation body weights, body weight change, food consumption, or maternal macroscopic findings. At 6.0 mg/kg/day, maternal effects were apparent from clinical findings (low body carriage, red material around the nose, thin appearance, loss of skin elasticity, and pale body color), lower gestation body weights, lower body weight change, and lower food consumption. No effect at dose levels ≤3.0 mg/kg/day was observed on pregnancy or uterine implantation data. At 6.0 mg/kg/day, 4/23 females at GD 20 had uterine implantation sites comprised entirely of resorbing foetuses (100 % post-implantation loss) and this contributed to decreases in mean number of viable foetuses and increases in mean post-implantation loss and mean number of resorption sites for the group. No effect of the test material was observed on foetal sex ratio, foetal body weight, or foetal external, visceral, or skeletal examinations. Lower maternal thymus weights were observed at all test material-treatment levels and an increased incidence of small thymus observed macroscopically in the 6.0 mg/kg/day animals.
In the context of this study, the toxicological significance of test material-related effects on thymus weights (decrease) in the absence of histopathological examination is unclear.
Under the conditions of the study the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity with the test material was 3.0 mg/kg/day. At dose levels of 0.75, 3.0, and 6.0 mg/kg/day, the test material was not teratogenic in the rat.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)